Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fracture Incidence Reduction And Safety Of TSE-424 (Bazedoxifene Acetate) Compared To Placebo And Raloxifene In Osteoporotic Postmenopausal Women

NCT00205777 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00205777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00205777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fracture Incidence Reduction And Safety Of TSE-424 (Bazedoxifene Acetate) Compared To Placebo And Raloxifene In Osteoporotic Postmenopausal Women
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2001
Completion date
September 30, 2010
Enrollment
7,609 (actual)
Sites
375

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis